Risk Adapted Management of Thyroid Cancer R Michael Tuttle, MD Professor of Medicine Endocrine Service Memorial Sloan Kettering Cancer Center New York,

Slides:



Advertisements
Similar presentations
Controversies in the Management of Differentiated Thyroid Carcinoma
Advertisements

Case 20 Thomas J. Giordano, M.D., Ph.D.. History A 54-year old man with a past medical history of goiter for approximately 4 years was followed by ultrasound.
Sunarto Reksoprawiro Division of Head & Neck Surgery, Department of Surgery Faculty of Medicine-Airlangga University/ Dr. Soetomo Hospital Surabaya, Indonesia.
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Hong CM, Ahn BC, Jeong SY, Lee SW, Lee J
The Thyroid Incidentaloma
AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
AJCC TNM Staging 7th Edition Thyroid Case #3
The Surgical Completeness of Robotic thyroidectomy : A prospective Comparative Study of Robotic versus conventional open thyroidectomy in papillary thyroid.
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Clinical Significance of Preoperative 18F-FDG PET Non- Avidity in Papillary Thyroid Carcinoma Do Hoon Koo 1, Ho-Young Lee 2, Kyu Eun Lee 3,4, So Won Oh.
Management of Papillary Ca Thyroid
AJCC Staging Moments AJCC TNM Staging 7th Edition Glottic Larynx Case #1 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New York,
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
Thyroid nodule History History Physical examination Physical examination –Euthyroid –Hypothyroid –Hyperthyroid Labs Labs –TSH –(antibodies)
Update in the Management of Thyroid Neoplasms University of Washington
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
Management of differentiated thyroid cancer Dr. Leung Tak Lun Canice North District Hospital.
Focus on endocrine neoplasia July 9, 2010 Rome Furio Pacini Dipartimento di Medicina Interna e Scienze Endocrino-Metaboliche Università di Siena Differentiated.
Role of Neck Dissection for Differentiated Thyroid CA Joint Hospital Surgical Grand Round NDH Dr. Alex TSANG.
AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #3 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Levothyroxine Suppressive Therapy in Thyroid Cancer R Michael Tuttle, MD Attending Endocrinologist Assistant Professor of Medicine Memorial Sloan Kettering.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
PET after Chemotherapy in Rhabdomyosarcoma Connective Tissue Oncology Society November 19, 2005 Michelle L. Klem, Leonard H. Wexler, Ravinder Grewal, Heiko.
AJCC Staging Moments AJCC TNM Staging 7th Edition Lung Case #1 Contributors: Valerie W. Rusch, MD Memorial Sloan-Kettering Cancer Center, New York, New.
Steven M. Larson, M.D. Memorial Sloan Kettering Cancer Center
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
ד"ר חגי מזא"ה כירורגיה אנדוקרינית מבואות כירורגיה שנה ד'
Management of the Locoregional Recurrence in Well-differentiated Thyroid Carcinoma 陳漢文.
Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J Nucl Med 2006; 47:616–624 報告者 : 蘇惠怡.
Chapter 28 Lung Cancer. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Objectives  Describe the epidemiology of.
Kerrington Smith, M.D. CTOS Nov 14, 2008
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
AJCC Staging Moments AJCC TNM Staging 7th Edition Supraglottic Larynx Case #2 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New.
Neck Cancer Head and STATEMENTS ON January 28, 2006 Frankfurt am Main, Germany Surgery Management of Lymph Node Metastases.
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
Thyroid Debate (Papillary Thyroid Cancer: Extent of Thyroidectomy) 30 Aug 2007 Surgery-OMMC JGGuerra, MD HCruz, MD.
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.
Regional Thyroid Cancer Guidelines Matthew Beasley Consultant Clinical Oncologist Bristol Cancer Institute Head & Neck SSG June 2015.
در مرکز پزشکی هسته ای دکتر دباغ – دکتر صادقی در خدمت شما هستیم مشهد، ملاصدرا 11 ، پلاک 1/4 Tel:+98(51) ; +98(51)
1. Clinical Impression? Differentials?. Thyroid Carcinoma commonly manifests as a painless, palpable, solitary thyroid nodule The patient's age at presentation.
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.
Treatment of thyroid nodules Depends on: –FNA cytological examination –Uptake of radioiodine –Size and patient preferences.
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
Thyroid carcinoma Thyroid carcinoma is uncommon Life time risk of being diagnosed with thyroid carcinoma is less than 1% (less than 1.5% of all adult.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Should Elderly Patients Undergo Additional Surgery After Non-Curative Endoscopic Resection for Early Gastric Cancer? Long-Term Comparative Outcomes R3.
Clinical Oncology & Nuclear Medicine Dep.
Symposium: Postoperative Management of Thyroid Cancer
Update in Thyroid Cancer Management
Challenges of Rare Cancers…
Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome  WILLIAM M.
Follicular variant of papillary thyroid carcinoma
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer ATA 2015 Dr Vahabi.
Can the American Thyroid Association Risk of Recurrence Predict Radioiodine Refractory Disease in Differentiated Thyroid Cancer Eur Thyroid J 2016;5:
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Cancer Staging.
郭其毓 劉建良 劉滄柏 林鉷彬 柯文清 鄭世平 蔡家騏 何恭誠
Cheng-Chiao Huang, MD, MSc
Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome  WILLIAM M.
Treatment Overview: The Multidisciplinary Team
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
Adjuvant Therapy in Gastric Cancer: Radiation Therapy Adds Nothing!
Presentation transcript:

Risk Adapted Management of Thyroid Cancer R Michael Tuttle, MD Professor of Medicine Endocrine Service Memorial Sloan Kettering Cancer Center New York, NY

Predicting Outcomes in Thyroid Cancer Common Staging Systems EORTCAGESAMESMACISOSUMSKCCTNM Age√√√√-√√ Gender√-√---- Size-√√√√√√ Multicen----√-- Grade-√---√- ETE√√√√√√√ LN----√√√ DM√√√√√√√ Resection---√--- Designed to predict death from disease, not recurrence Dean DS and Hay ID. Cancer Control, 2000; 7(3): p

Differentiated Thyroid Cancer Mazzaferri. JCEM Age (yrs) at time of initial therapy Percent Recurrence Death Distant Recurrence

Limitations  Current Staging systems Are designed to predict death, not recurrence Don’t adequately incorporate  Molecular findings  Histological subtyping Do not adjust to new data obtained during follow up Are not altered by duration of disease free survival  As clinicians Begin with initial risk stratification Obtain new data every 6 months Integrated into ongoing and updated risks of recurrence and death

Management Based on Risk Risk of DeathRisk of Recurrence Risk of Distant Metastases Risk of Not Responding to Therapy (Risk of Persistent Disease) What risk are we talking about?

Risk Adapted Management Risk of DeathRisk of Recurrence Guide Initial Treatment Recommendations (Extent of surgery, RAI ablation, EBRT etc)

MSKCC Strategy for Risk Stratification Age Gender Size Extent Grade Distantmets < 45 yrs Female < 4 cm Intraglandular Low Absent Low >45 yrs Male >4 cm Extraglandular High Present HighIntermediate Mixture of Features Shah,Shaha, MSKCC

Risk Stratification Age Gender Size Extent Grade Distantmets < 45 yrs Female < 4 cm Intraglandular Low Absent >45 yrs Male >4 cm Extraglandular High Present LowHighIntermediate Mixture of Features MSKCC Death Rate 40% <1% 38% 15% 22% 54% Shah,Shaha, MSKCC

Risk Stratification for Death from Thyroid Cancer Very LowLowIntermediateHigh Age Size Histology Resection LN DM Tuttle. Endocrine Practice 14: , 2008.

Risk Stratification for Death from Thyroid Cancer Very LowLowIntermediateHigh Age< 45 years Size Histology < 1 cm PTC* ResectionComplete LNNo DMNo *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk Stratification for Death from Thyroid Cancer Very LowLowIntermediateHigh Age< 45 years Size Histology < 1 cm PTC* 1-4 cm PTC* ResectionComplete LNNo+/- DMNo *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk Stratification for Death from Thyroid Cancer Very LowLowIntermediateHigh Age< 45 years >45 years PTC > 4 cm Size Histology < 1 cm PTC* 1-4 cm PTC* ?Other > 1-2 cm ResectionComplete Incomplete LNNo+/- DMNo Yes *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk Stratification for Death from Thyroid Cancer Very LowLowIntermediateHigh Age< 45 years Young patients (<45 yrs)  Classic PTC > 4cm  Worrisome histology >45 years PTC > 4 cm Size Histology < 1 cm PTC* 1-4 cm PTC* Older patients (> 45 yrs)  Classic PTC < 4 cm  Worrisome histology ?Other > 1-2 cm ResectionComplete Incomplete LNNo+/- DMNo Yes *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk of Recurrence of Thyroid Cancer LowIntermediateHigh Age Size Histology LN *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk of Recurrence of Thyroid Cancer LowIntermediateHigh AgeAny age Size< 1 cm HistologyClassic PTC* LNNone apparent *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk of Recurrence of Thyroid Cancer LowIntermediateHigh AgeAny age 60 yrs Size< 1 cm> 4 cm HistologyClassic PTC*Other Gross ETE Gross Vasc Inv LNNone apparentPresent *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk of Recurrence of Thyroid Cancer LowIntermediateHigh AgeAny age yrs 60 yrs Size< 1 cm1-4 cm> 4 cm HistologyClassic PTC*Classic PTC Minor ETE Minor Vasc Inv Other Gross ETE Gross Vasc Inv LNNone apparentPresent or absentPresent *Classic PTC, intrathyroidal Tuttle. Endocrine Practice 14: , 2008.

Risk Adapted Management of Low Risk Patients Very Low Age< 45 years Size Histology < 1 cm PTC* ResectionComplete LNNo DMNo Death Less than total thyroidectomy is acceptable RAI ablation not required Low AgeAny age Size< 1 cm HistologyClassic PTC* LNNone apparent Recurrence Tuttle. Endocrine Practice 14: , 2008.

Risk Adapted Management of High Risk Patients High Age>45 years PTC > 4 cm Size Histology Other > 1-2 cm ResectionIncomplete LN+/- DMYes High Age 60 yrs Size> 4 cm HistologyOther Gross ETE Gross Vasc Inv LNPresent Recurrence Death Total thyroidectomy RAI ablation Tuttle. Endocrine Practice 14: , 2008.

Risk Adapted Management Risk of DeathRisk of Recurrence Initial SurgeryRAI remnant ablation Very LowLowLobectomy or total thyroidectomy Not required LowLobectomy or total thyroidectomy Not required LowIntermediateTotal thyroidectomyFor selected patients* HighTotal thyroidectomyYes IntermediateTotal thyroidectomyFor most patients Intermediate HighTotal thyroidectomyYes IntermediateTotal thyroidectomyYes High Total thyroidectomyYes Tuttle. Endocrine Practice 14: , 2008.

Expected Benefit FactorsDescriptionDecrease risk of death Decrease risk of recurrence May facilitate initial staging and follow up T11cm or less, intrathyroidal 1-2 cm, intrathyroidal T2> 2 to 4 cm, intrathyroidal T3> 4cm < 45 yrs old > 45 yrs old Any size, any age, minimal extrathyroidal extension T4Any size with gross extrathyroidal extension Risk Adapted Management Based on TNM (AJCC) Staging RAI remnant ablation ATA Thyroid Cancer Guidelines, Revised 2009

Expected Benefit FactorsDescriptionDecrease risk of death Decrease risk of recurrence May facilitate initial staging and follow up T11cm or less, intrathyroidal 1-2 cm, intrathyroidal T2> 2 to 4 cm, intrathyroidal T3> 4cm < 45 yrs old > 45 yrs old Any size, any age, minimal extrathyroidal extension T4Any size with gross extrathyroidal extension Potential Benefits of RAI Ablation New Table in the Updated ATA Thyroid Cancer Guidelines No Yes NoConflicting DataYes NoConflicting DataYes No Yes No Conflicting Data Yes Inadequate Data Yes ATA Thyroid Cancer Guidelines, Revised 2009

Expected Benefit FactorsDescriptionDecrease risk of death Decrease risk of recurrence May facilitate initial staging and follow up Nx, N0No clinical or pathologic LN documented N1< 45 yrs old > 45 yrs old M1Distant metastasis present No Conflicting Data Yes No Yes Potential Benefits of RAI Ablation New Table in the Updated ATA Thyroid Cancer Guidelines ATA Thyroid Cancer Guidelines, Revised 2009

Proposed Language ATA Guidelines  Radioiodine ablation is recommended for all patients with known distant metastases, gross extrathyroidal extension of the tumor regardless of tumor size, or primary tumor size greater than 4 cm even in the absence of other higher risk features  Radioiodine ablation is recommended for selected patients with 1-4 cm thyroid cancers confined to the thyroid, documented lymph node metastases, or other higher risk features when the combination of age, tumor size, lymph node status and individual histology predicts an intermediate to high risk of recurrence or death from thyroid cancer  Radioiodine ablation is not recommended for patients with unifocal cancer less than 1 cm without other higher risk features ATA Thyroid Cancer Guidelines, Revised 2009

Risk Adapted Management Risk of DeathRisk of Recurrence Guide Initial Treatment Recommendations (Extent of surgery, RAI ablation, EBRT etc) Guide Intensity and Timing of Follow up (Tg, US, RAI scans, PET scans, CT scans etc)

Risk Adapted Management First 2 years of follow up LowIntermediateHigh Supp Tg Stim Tg Neck US Dx WBS MRI, CT FDG PET Tuttle. Endocrine Practice 14: , 2008.

Risk Adapted Management First 2 years of follow up LowIntermediateHigh Supp TgQ 6 months Stim TgNot required Neck USQ year x2 Dx WBSNot required MRI, CTNot required FDG PETNot required Tuttle. Endocrine Practice 14: , 2008.

Risk Adapted Management First 2 years of follow up LowIntermediateHigh Supp TgQ 6 months Stim TgNot required1-2 years Neck USQ year x2 Dx WBSNot required1-2 years MRI, CTNot required FDG PETNot required Tuttle. Endocrine Practice 14: , 2008.

Risk Adapted Management First 2 years of follow up LowIntermediateHigh Supp TgQ 6 months Stim TgNot required1-2 years Neck USQ year x2 Dx WBSNot required1-2 years MRI, CTNot required If Tg elevated or high clinical suspicion FDG PETNot required If Tg elevated, RAI scan negative Response to Therapy Variables (Tg, US, RAI scans, PET scans, CT scans etc) Tuttle. Endocrine Practice 14: , 2008.

Response to Therapy Assessment Excellent response Acceptable Response Incomplete Response Supp Tg Stim Tg Trend in Tg Anti-Tg antibodies Not included in current risk stratification systems Tuttle. Endocrine Practice 14: , 2008.

Response to Therapy Assessment Excellent response Acceptable Response Incomplete Response Supp TgUndetectable Stim TgUndetectable Trend in Tg Remains undetectable Anti-Tg antibodies Absent Not included in current risk stratification systems Tuttle. Endocrine Practice 14: , 2008.

Response to Therapy Assessment Excellent response Acceptable Response Incomplete Response Supp TgUndetectableDetectable but < 1 ng/mL Stim TgUndetectable< 10 ng/mL Trend in Tg Remains undetectable Declining Anti-Tg antibodies AbsentAbsent or declining Not included in current risk stratification systems Tuttle. Endocrine Practice 14: , 2008.

Response to Therapy Assessment Excellent response Acceptable Response Incomplete Response Supp TgUndetectableDetectable but < 1 ng/mL > 1 ng/mL Stim TgUndetectable< 10 ng/mL> 10 ng/mL Trend in Tg Remains undetectable DecliningStable or rising Anti-Tg antibodies AbsentAbsent or decliningPersistent or rising Not included in current risk stratification systems Tuttle. Endocrine Practice 14: , 2008.

Response to Therapy Assessment Neck Ultrasonography ExcellentAcceptableIncomplete NED Tuttle. Endocrine Practice 14: , 2008.

Response to Therapy Assessment Neck Ultrasonography ExcellentAcceptableIncomplete NEDNon-specific changes in thyroid bed Probable inflammatory lymph nodes Stable millimeter sized cervical LN even if abnormal by US criteria Tuttle. Endocrine Practice 14: , 2008.

Response to Therapy Assessment Neck Ultrasonography ExcellentAcceptableIncomplete NEDNon-specific changes in thyroid bed Probable inflammatory lymph nodes Stable millimeter sized cervical LN even if abnormal by US criteria Evidence of structurally significant recurrent/persistent disease in the thyroid bed (> 1 cm) Cervical lymph nodes (> 1cm), particularly if structurally progressive or FDG avid Tuttle. Endocrine Practice 14: , 2008.

Secondary Risk Stratification 2 years after initial therapy Based on Accumulating Clinical Data ExcellentAcceptableIncomplete Lower our initial risk estimates Response to Therapy Tuttle. Endocrine Practice 14: , 2008.

Secondary Risk Stratification 2 years after initial therapy Based on Accumulating Clinical Data ExcellentAcceptableIncomplete Lower our initial risk estimates Little change in our initial risk estimates Response to Therapy Tuttle. Endocrine Practice 14: , 2008.

Secondary Risk Stratification 2 years after initial therapy Based on Accumulating Clinical Data ExcellentAcceptableIncomplete Lower our initial risk estimates Little change in our initial risk estimates Raise our initial risk estimates Response to Therapy Tuttle. Endocrine Practice 14: , 2008.

Risk Stratification An active, ongoing process Risk Assessment Treatment Plan Response to Therapy Follow up Strategy Tuttle. Endocrine Practice 14: , 2008.

Risk Adapted Management of Thyroid Cancer Individualized Recommendations Risk Appropriate Therapy Risk Appropriate Follow up Minimizes Unnecessary Treatments and Testing Maximizes Benefits of Therapy